NDAORALTABLETPriority Review
Approved
May 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Mechanism of Action
Stem Cell Factor (KIT) Receptor Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Clinical Trials (1)
A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)
Started Apr 2020
39 enrolled
Gastrointestinal Stromal Tumors
Loss of Exclusivity
LOE Date
Oct 6, 2042
202 months away
Patent Expiry
Oct 6, 2042
Exclusivity Expiry
May 15, 2027